Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI neurotherapeutics discovery platform for epilepsy/autism/Parkinson's with multimodal neural AI; animal lab + proof-of-concept + 2 patents in 1.5 months; $25M Philippines lab investment competing with Recursion for AI-driven CNS gene therapy.
Exin Therapeutics is a San Francisco-based AI-powered neurotherapeutics drug discovery company — pioneering genetic therapies that target neural activity to treat epilepsy, autism spectrum disorder symptoms, Parkinson's disease, and other neurological conditions using a multimodal AI platform that predicts therapeutic candidate potential across multiple neural disorders simultaneously. Using neural activity recordings, behavioral assays, and transcriptomics data as inputs, Exin's AI models identify genetic intervention targets and predict therapeutic outcomes before entering animal studies — compressing the target identification timeline that traditional neuroscience drug discovery requires. The company established an animal research facility, obtained proof-of-concept results in mice, and filed two provisional patents within 1.5 months of San Francisco operations, and is investing approximately $25 million to build the Philippines' first neurotherapeutics laboratory.
UK private chef marketplace with 900+ chefs and $6.7M annualized revenue; 45-65% word-of-mouth growth backed by YC and Goodwater Capital expanding to US in 2025.
yhangry is a London-based marketplace connecting customers with 900+ private chefs for in-home dining experiences — enabling individuals, couples, and groups to book a professional chef who shops for ingredients, cooks a multi-course meal in the customer's kitchen, and handles cleanup, for occasions ranging from date nights to dinner parties and corporate events. Founded in 2022 and backed by Y Combinator, Goodwater Capital, and prominent angels with $3.5 million raised, yhangry achieved $6.7 million in annualized revenue in 2024 with 5,300+ bookings and prepares for US expansion in 2025.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.